International Journal of Dermatology最新文献

{"title":"A Case of Facial Rosai-Dorfman Disease With External Ear, Laryngeal, and Eye Involvement.","authors":"Gaobo Ruan, Wumei Zhao, Bo Huang, Wei Wu, Wei-Jiang Chen, Song Wang, Shi-Jun Shan","doi":"10.1111/ijd.17864","DOIUrl":"https://doi.org/10.1111/ijd.17864","url":null,"abstract":"","PeriodicalId":13950,"journal":{"name":"International Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severity and Therapeutic Decisions Based on Lesion Location in Patients With Hidradenitis Suppurativa.","authors":"Daniel Muñoz-Barba, Sofía Haselgruber de Francisco, Francisco Javier León-Pérez, Carlos Cuenca-Barrales, Salvador Arias-Santiago, Manuel Sánchez-Díaz, Alejandro Molina-Leyva","doi":"10.1111/ijd.17861","DOIUrl":"https://doi.org/10.1111/ijd.17861","url":null,"abstract":"<p><strong>Background: </strong>Hidradenitis suppurativa (HS) is a chronic inflammatory disease for which several phenotypic classifications have been proposed in recent years to optimize medical care. The aim of this study was to define a new classification of HS based on the anatomical distribution of lesions, serving as a tool for therapeutic decision-making.</p><p><strong>Methods: </strong>This cross-sectional study with consecutive sampling included patients attending their first medical consultation at the Hidradenitis Suppurativa Unit of Virgen de las Nieves University Hospital in Granada, Spain, between January 1, 2017, and March 1, 2024. Patients were classified into four groups based on the anatomical distribution of HS: Upper, Atypical, Lower, and Progressor HS. Sociodemographic variables, personal history, and HS-related variables were collected.</p><p><strong>Results: </strong>A total of 557 patients were included, with a similar proportion of men and women. Patients with the Upper type exhibited milder forms of HS and underwent surgical treatment more frequently. In contrast, those with the Progressor type presented more severe forms of HS and required more immunomodulatory treatment. Patients in the Atypical and Lower groups showed more heterogeneity in therapeutic approaches, although the presence of lesions in specific locations may help predict the need for early initiation of more aggressive treatments.</p><p><strong>Conclusions: </strong>We propose a new HS classification based on the location of lesions. This classification can be used alone or in conjunction with previous ones to identify patients at higher risk of progression and to guide therapeutic decision-making.</p>","PeriodicalId":13950,"journal":{"name":"International Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lichen Sclerosus Is Associated With Atopic Conditions: A Retrospective Population-Level Study.","authors":"Alexa C Kassels, Jagmeet S Arora, Christina N Kraus","doi":"10.1111/ijd.17854","DOIUrl":"https://doi.org/10.1111/ijd.17854","url":null,"abstract":"","PeriodicalId":13950,"journal":{"name":"International Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linear Immunoglobulin A/G Bullous Dermatosis With Dual Autoimmunity to BP230 and Type VII Collagen.","authors":"Yuanhong Liu, Xiaopo Wang","doi":"10.1111/ijd.17859","DOIUrl":"https://doi.org/10.1111/ijd.17859","url":null,"abstract":"","PeriodicalId":13950,"journal":{"name":"International Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acquired Idiopathic Generalized Anhidrosis and Frontal Fibrosing Alopecia: Possible Evidence for a Shared Autoimmune Pathogenesis.","authors":"Shota Nakayama, Akinori Kawakami, Kenji Kabashima","doi":"10.1111/ijd.17866","DOIUrl":"https://doi.org/10.1111/ijd.17866","url":null,"abstract":"","PeriodicalId":13950,"journal":{"name":"International Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence in Dermatology: A Comprehensive Review of Approved Applications, Clinical Implementation, and Future Directions.","authors":"William J Nahm, Nayyab Sohail, Joshua Burshtein, Mohamad Goldust, Maria Tsoukas","doi":"10.1111/ijd.17847","DOIUrl":"https://doi.org/10.1111/ijd.17847","url":null,"abstract":"<p><p>This comprehensive review examines artificial intelligence (AI) applications in dermatology, approved by the United States (U.S.) Food and Drug Administration (FDA) and international organizations, evaluating their clinical implementation and impact on healthcare delivery. We identified fifteen regulatory-approved AI devices globally, including three FDA-approved systems in the U.S. The FDA-approved devices primarily focused on melanoma and skin cancer detection through specialized hardware, while international platforms emphasized broader applications, mobile accessibility, and condition-specific tools for managing various skin conditions. Beyond these specific tools, we analyzed how AI can enhance clinical dermatology through screening systems, diagnostic support, administrative automation, and practice optimization. AI's integration into medical education can provide immediate feedback, support resident training, and complement traditional instruction, while patient education applications can improve treatment adherence through personalized content delivery. While AI shows promise across these domains, successful implementation requires addressing challenges in representation disparities, data privacy, algorithmic fairness, and clinical workflow integration. Future development should focus on standardized validation protocols, diverse training sets, robust real-world studies, and comprehensive assessment of patient outcomes beyond traditional performance metrics. AI's role appears most effective as augmentation to clinical expertise, particularly in improving access to specialized care and supporting clinical decision-making.</p>","PeriodicalId":13950,"journal":{"name":"International Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of Psoriasis in Poland: Prevalence, Incidence, and Mortality Rates.","authors":"Joanna Bartosińska, Jacek C Szepietowski, Dorota Raczkiewicz, Christopher E M Griffiths, Darren M Ashcroft, Alison K Wright, Krzysztof Podwójcic, Jakub Turcza, Michał Maluchnik, Agnieszka Chłoń-Domińczak, Dorota Krasowska","doi":"10.1111/ijd.17848","DOIUrl":"https://doi.org/10.1111/ijd.17848","url":null,"abstract":"<p><strong>Background: </strong>Although the data on psoriasis epidemiology included in the Global Psoriasis Atlas (GPA) provide valuable information on psoriasis prevalence worldwide, the GPA database is still incomplete. Therefore, the aim of the study was to assess the prevalence, incidence, and mortality rates of psoriasis and its types in Poland based on the data registered by the National Health Fund (NHF).</p><p><strong>Methods: </strong>The study included psoriasis patients registered at least twice in the Polish NHF database between 2010 and 2023.</p><p><strong>Results: </strong>At the end of 2023, 639,662 living psoriasis patients had been registered in the Polish NHF database, which constituted 1.70% of the Polish general population. The percentage of female psoriasis patients was found to be higher (54.95%) than male patients (45.05%). Of all the Polish NHF-registered psoriasis patients, plaque psoriasis affected 95.66%, pustular psoriasis 3.05%, psoriatic arthritis 7.20%, and guttate psoriasis 0.27%. In comparison to the general Polish population, psoriasis prevalence was observed to be lower in children (0.84%). The all-cause mortality rate among psoriasis patients was found to be higher in comparison to the general Polish population, with a higher mortality rate noted in male psoriasis patients.</p><p><strong>Conclusions: </strong>The NHF database we studied suggests a direct relationship between the prevalence, incidence, and all-cause mortality rates in psoriasis and patients' age and sex. However, the study also revealed a decrease in mortality rates and a slow increase in the prevalence of psoriasis in the Polish population, which calls for further studies.</p>","PeriodicalId":13950,"journal":{"name":"International Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Upregulated NOTCH2 Expression Is Implicated in the Clinical Aggressiveness of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma.","authors":"Yi-Pei Lee, Fahimeh Razegphpour, Emilia Sorescu, Markus Stücker, Thilo Gambichler","doi":"10.1111/ijd.17844","DOIUrl":"https://doi.org/10.1111/ijd.17844","url":null,"abstract":"<p><strong>Background: </strong>Atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) represent clinicopathological variants of a spectrum. It is known that AFX and PDS tumors harbor frequent NOTCH1/2 mutations. However, the expression of Notch signaling pathway-associated proteins in both tumor cells has not been studied before.</p><p><strong>Methods: </strong>We conducted an immunohistochemical study by performing NOTCH1, NOTCH2, NICD, and HES1 staining on the most representative formalin-fixed paraffin-embedded (FFPE) tumor tissues out of sixty-two patients with the first diagnosis of either AFX (n = 33) or PDS (n = 29) in a single tertiary medical center.</p><p><strong>Results: </strong>Ten patients (PDS, n = 9; AFX, n = 1) had disease progression in terms of locoregional relapse, including local recurrence and regional lymph node metastasis, with a median time-to-(first)-recurrence interval of 8 months after a wide local excision. Among all the Notch expression profiles, only the upregulated NOTCH2 expression has a positive correlation with disease progression [odds ratio (OR): 1.02, 95% confidence interval (CI): 1-1.04, p = 0.029]. Furthermore, HES1 is activated through the NOTCH2 signaling pathway (r (60) = 0.27, p = 0.032) rather than NOTCH1, and NOTCH1 does not appear to be functionally active.</p><p><strong>Conclusions: </strong>Upregulated NOTCH2 expression plays a significant role in disease progression, in part through the canonical signaling pathway involving the downstream effector HES1. Targeting NOTCH2 signaling might hold therapeutic promise in patients with disease progression.</p>","PeriodicalId":13950,"journal":{"name":"International Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lymphocyte Transformation Tests and Patch Tests to Identify Drugs Potentially Associated With Bullous Pemphigoid Development.","authors":"Belen de Nicolas-Ruanes, Carlos Fernandez-Lozano, Patricia Gutierrez-Canales, Asuncion Ballester-Martinez, Natalia Rodriguez-Otero, Javier Martinez-Botas, Belén de la Hoz Caballer, Ana Andres-Martin, Emilio Solano-Solares, Maria Esther Gomez-Salazar Lopez-Silanes, Laura Gisella Diaz-Montalvo, Diana M Arrebola, Vivian Lizeth Stewart-Delcid, Emilio Garcia-Mouronte, Carlos Azcarraga-Llobet, Emilio Berna-Rico, Sonia Ortega-Sanchez, Montserrat Fernandez-Guarino","doi":"10.1111/ijd.17849","DOIUrl":"https://doi.org/10.1111/ijd.17849","url":null,"abstract":"<p><strong>Background: </strong>Bullous pemphigoid (BP) is the most common autoimmune blistering disease, with a rising incidence in the elderly. BP is associated with multiple triggering factors, including drug exposure. However, evidence in this respect is limited, and the underlying immune mechanisms remain unknown. Our study aims to identify the role of specific drugs in BP pathogenesis using in vitro lymphocyte transformation tests (LTT) and in vivo patch testing, aiding in the differentiation between truly associated drugs and coincidental associations.</p><p><strong>Methods: </strong>Thirty-three patients with suspected BP and no ongoing systemic treatment were enrolled. LTT and patch tests were conducted 3 months after diagnosis. BP disease activity was assessed using the Bullous Pemphigoid Disease Activity Index (BPDAI) at diagnosis and at follow-up visits at 3 and 6 months.</p><p><strong>Results: </strong>LTT results were positive in 60% of patients for dipeptidyl peptidase 4 inhibitors, loop diuretics, hydrochlorothiazide, levetiracetam, nivolumab, enalapril, and amlodipine. Patients showed a reduction in BPDAI over the study period, regardless of LTT results. Although limited by the low sample size, positive LTT patients showed a trend toward clinical improvement when the implicated drug was discontinued. Patch testing was positive in one patient, who also had a corresponding positive LTT.</p><p><strong>Conclusions: </strong>Our findings demonstrate the existence of a potential role for certain drugs in BP pathogenesis, suggesting that these drugs may trigger the disease in genetically predisposed individuals. Although further studies are needed, LTT may serve as a useful and available tool in the management of BP patients in the future.</p>","PeriodicalId":13950,"journal":{"name":"International Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab for the Treatment of Cutaneous Immune-Related Adverse Events: A Systematic Review.","authors":"Ioannis-Alexios Koumprentziotis, Aikaterini Niforou, Antonios Tsimpidakis, Christos Nikolaou, Alexander Stratigos, Vasiliki Nikolaou","doi":"10.1111/ijd.17850","DOIUrl":"https://doi.org/10.1111/ijd.17850","url":null,"abstract":"<p><p>The emergence of immune checkpoint inhibitors has revolutionized the landscape of cancer treatment in the modern era. However, cutaneous immune-related adverse events (cirAEs) are common, significantly affecting patients' quality of life and often leading to treatment discontinuation, which may compromise oncological outcomes. Dupilumab, an immunoglobulin G4 (IgG4) human monoclonal antibody targeting interleukin (IL)-4 and IL-13 receptors, is widely used for dermatologic conditions but remains unapproved for cirAEs due to the limited and scattered supporting evidence. This review aimed to summarize the available evidence regarding the use of dupilumab for the management of cirAEs. A systematic review was conducted using MEDLINE/PubMed, Scopus, and Web of Science in adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. In total, 25 publications met the eligibility criteria and were included, reporting 136 patients who were diagnosed with 140 cirAEs and were treated with dupilumab. The most frequently treated cirAEs were eczematous rashes, bullous pemphigoid, and maculopapular/morbilliform rashes. Dupilumab was found to be highly effective, with most patients achieving complete or partial responses, even when affected by two concomitant cirAEs. An acceptable safety profile was demonstrated regarding both adverse events and oncological safety, with no additional concerns to be raised. The findings may be encouraging but are limited by the relatively small number of patients treated and the nature of the included studies, with most of them being case reports and case series. More research is warranted, along with more clinical studies, prospective in design, focused on relevant clinical outcomes of this dupilumab-treated subset of patients.</p>","PeriodicalId":13950,"journal":{"name":"International Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}